Accendra Health (DE:6OM)
FRANKFURT:6OM
6OM Stock Chart & Stats
€2.62
€0.30(2.31%)
At close: 4:00 PM EST
€2.62
€0.30(2.31%)
Day’s Range― - ―
52-Week Range€1.51 - €8.00
Previous CloseN/A
Volume0.00
Average Volume (3M)89.00
Market Cap
€186.58M
Enterprise Value€2.05B
Total Cash (Recent Filing)€336.88M
Total Debt (Recent Filing)€2.17B
Price to Earnings (P/E)―
Beta1.33
Next Earnings
Jul 31, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-14.05
Shares Outstanding76,583,700
10 Day Avg. Volume267
30 Day Avg. Volume89
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.47
Price to Sales (P/S)0.08
P/FCF Ratio-0.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.81Price Target Upside45.42% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)0.6
Revenue Forecast (FY)€2.21B
Bulls Say, Bears Say
Bulls Say
Accounting Adjustment And Reported EarningsAnalyst notes that reclassification of certain add‑backs into adjusted operating income increased adjusted earnings per share without materially changing EBITDA, supporting headline profitability metrics.
Operational Initiatives And Technology InvestmentsAnalyst points to management's tighter operational focus, investments in technology, and improved collections as measures likely to reduce costs and improve cash generation.
Product-line Revenue StrengthAnalyst highlights robust performance in sleep apnea, urology, and ostomy businesses that underpin revenue resilience and can partially offset weakness in respiratory products.
Bears Say
Capital Structure And Leverage RiskAnalyst flags elevated debt levels and capital structure concerns that increase financial risk and limit flexibility for strategic investments or debt reduction.
Competitive, Reimbursement And Product Substitution PressuresAnalyst cautions that competitive bidding, a shift to pharmacy channels for diabetes fulfillment, adoption of GLP‑1 therapies, and reimbursement pressures may constrain long‑term revenue growth and pricing power.
Customer Loss And Stranded Separation CostsAnalyst warns that the loss of a major customer and stranded costs from the company's separation could continue to depress margins and weigh on near‑term profitability.
Accendra Health News
6OM FAQ
What was Accendra Health’s price range in the past 12 months?
Accendra Health lowest stock price was €1.51 and its highest was €8.00 in the past 12 months.
What is Accendra Health’s market cap?
Accendra Health’s market cap is €186.58M.
When is Accendra Health’s upcoming earnings report date?
Accendra Health’s upcoming earnings report date is Jul 31, 2026 which is in 58 days.
How were Accendra Health’s earnings last quarter?
Accendra Health released its earnings results on May 11, 2026. The company reported -€0.034 earnings per share for the quarter, beating the consensus estimate of -€0.083 by €0.049.
Is Accendra Health overvalued?
According to Wall Street analysts Accendra Health’s price is currently Undervalued.
Does Accendra Health pay dividends?
Accendra Health does not currently pay dividends.
What is Accendra Health’s EPS estimate?
Accendra Health’s EPS estimate is -0.07.
How many shares outstanding does Accendra Health have?
Accendra Health has 76,583,700 shares outstanding.
What happened to Accendra Health’s price movement after its last earnings report?
Accendra Health reported an EPS of -€0.034 in its last earnings report, beating expectations of -€0.083. Following the earnings report the stock price went down -5.096%.
Which hedge fund is a major shareholder of Accendra Health?
Currently, no hedge funds are holding shares in DE:6OM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Accendra Health Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€3.81 (45.42% Upside)
€3.81 (45.42% Upside)
Blogger Sentiment
Bullish
DE:6OM Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
-58.19%
12-Months-Change
Fundamentals
Return on Equity
264.54%
Trailing 12-Months
Asset Growth
-50.25%
Trailing 12-Months
Company Description
Accendra Health
Accendra Health, Inc., together with its subsidiaries, operates as a healthcare solutions company worldwide. The company operates in two segments, Products & Healthcare Services and Patient Direct. The Products & Healthcare Services segment offers a portfolio of products and services to healthcare providers and manufacturers. Its portfolio of medical and surgical supplies includes branded products and its proprietary products. This segment also offers services to healthcare providers, including supplier management, analytics, inventory management, and clinical supply management; and various programs to provide outsourced logistics and marketing solutions to its suppliers. The Patient Direct segment provides products and services for in-home care and delivery across diabetes treatment, home respiratory therapy, and obstructive sleep apnea treatment. This segment also supplies a range of other home medical equipment; and patient care products, including ostomy, wound care, urology, and incontinence and other products and services. The company serves multi-facility networks of healthcare providers, independent hospitals, surgery centers, physicians' practices, and networks of hospitals directly, as well as indirectly through third-party distributors. Accendra Health, Inc. was formerly known as Owens & Minor, Inc. and changed its name Accendra Health, Inc. in December 2025. The company was founded in 1882 and is based in Glen Allen, Virginia.
6OM Company Deck
6OM Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a mix of strong strategic and financial progress — notably the successful separation, margin transformation, balance sheet optimization commitments, $82M equipment sale and $52M one‑time gain, and operational wins in sleep therapy — while also acknowledging meaningful near‑term pressures: a 6.8% revenue decline, collection and cost headwinds, slightly negative free cash flow in Q1, and an expected ~ $40M annualized increase in cash interest post‑refinancing. Management emphasized that underlying revenue (ex‑large payor) was roughly +1% and that debt reduction and cost‑savings remain priorities, framing the near‑term drawbacks as manageable steps in service of a stronger long‑term standalone profile.View all DE:6OM earnings summaries6OM Stock 12 Month Forecast
Average Price Target
€3.81
▲(45.42% Upside)
Technical Analysis
Cencora
―
Cardinal Health
―
Henry Schein
―
McKesson
―
Guardian Pharmacy Services, Inc. Class A
―
Options Prices
Currently, No data available
---